Every week, The American Journal of Managed Care® recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast.
Every week, The American Journal of Managed Care® recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast.
This week, the top managed care news included the FDA's approval of a $2.1 million gene therapy; a study revealing that the worldwide need for palliative care will nearly double by 2060; the FDA granting priority review to Amarin’s Vascepa for a cardiovascular indication.
You may need to log in to the website to access this podcast.
Listen above or through one of these podcast services:
FDA Approves Gene Therapy With $2.1M Price Tag for Spinal Muscular Atrophy in Pediatric Patients
Amarin's High-Dose Fish Oil Pill Cuts Total CV Event Risk 30% in Study
The American Journal of Managed Care®—May 2019
Open Doors to Primary Care Should Add a “Screen” to Reduce Low-Value Care
American Society of Clinical Oncology Annual Meeting 2019
Read more about the stories in this podcast:
What It Takes to Improve Guideline-Based Heart Failure Care With Ty J. Gluckman, MD
August 5th 2025Explore innovative strategies to enhance heart failure treatment through guideline-directed medical therapy, remote monitoring, and artificial intelligence–driven solutions for better patient outcomes.
Listen
Semaglutide Linked to Cardiovascular Gains, but Also Higher Health Spending
August 8th 2025A real-world study found that semaglutide prescriptions were associated with improvements in weight, blood pressure, and cholesterol, but also a $80 monthly rise in health care spending outside of drug costs.
Read More